Biopharma's Profit Paradox: Drug Makers Lag in Risk-Adjusted Returns Despite Heavy R&D Investments
Event summary
- Pacific Research Institute's analysis of 1,200+ U.S. health care companies (2022-2024) shows biopharma's average EVA at just 1.1%, below the overall industry average of 6.3%.
- Health insurers and PBMs earned an average EVA of 33.1% despite lower R&D investments.
- Biopharma companies invested 33.2% of revenues in R&D, nearly ten times the U.S. industry average.
The big picture
The analysis challenges conventional wisdom about biopharma profitability, revealing that despite heavy R&D investments, drug makers earn among the lowest risk-adjusted returns in health care. This finding comes amid ongoing debates over government intervention in drug pricing and could reshape arguments for or against price controls. The data suggests that current pricing systems may be distorting market incentives, potentially affecting future innovation.
What we're watching
- Regulatory Pressure
- How policymakers will respond to findings challenging the justification for drug price controls.
- Investment Trends
- Whether lower risk-adjusted returns will deter future biopharma R&D investments.
- Market Reactions
- The pace at which this data influences stakeholder positions in the drug pricing debate.